Automate Your Wheel Strategy on ACLX
With Tiblio's Option Bot, you can configure your own wheel strategy including ACLX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ACLX
- Rev/Share 1.39
- Book/Share 7.5449
- PB 8.4401
- Debt/Equity 0.1276
- CurrentRatio 4.9275
- ROIC -0.3557
- MktCap 3509194974.0
- FreeCF/Share -2.2167
- PFCF -28.6495
- PE -21.6644
- Debt/Assets 0.0821
- DivYield 0
- ROE -0.3527
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ACLX | Redburn Atlantic | -- | Buy | -- | $109 | Oct. 8, 2024 |
| Initiation | ACLX | Cantor Fitzgerald | -- | Overweight | -- | -- | Sept. 3, 2024 |
News
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma
Published: May 14, 2025 by: Business Wire
Sentiment: Neutral
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced new positive data from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple myeloma (RRMM). These data will be presented during an oral presentation at the EHA2025 Congress in Milan.
Read More
Baron Health Care Fund Q1 2025 Top Contributors And Detractors
Published: April 29, 2025 by: Seeking Alpha
Sentiment: Positive
Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals saw increased investor confidence in its cystic fibrosis franchise and evolving pipeline, including promising non-opioid pain treatments and kidney disease drugs. UnitedHealth Group's shares gained as 2024 headwinds subsided, Medicare Advantage rates improved, and higher-margin Optum segments grew, insulating it from tariff impacts.
Read More
Arcellx Impressive Safety Data Leaves Doubts
Published: March 17, 2025 by: Seeking Alpha
Sentiment: Positive
Arcellx's innovative cell therapy platform shows promising potential in treating multiple myeloma, a significant unmet medical need. Strong clinical trial results and strategic partnerships bolster confidence in Arcellx's growth trajectory and market position. Clarity is needed around mechanistic differentiation on D-Domain safety results before fully buying into the story.
Read More
About Arcellx, Inc. (ACLX)
- IPO Date 2022-02-04
- Website https://arcellx.com
- Industry Biotechnology
- CEO Mr. Rami Elghandour
- Employees 163